Your AI-Trained Oncology Knowledge Connection!
With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Patients with advanced prostate cancer benefitted from relugolix vs leuprolide regardless of baseline testosterone level.
The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.
Study results indicated that the small molecule HIF-2α inhibitor MK-6482 induced positive results in patients with certain Von Hippel-Lindau disease–associated solid tumors.
Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.
Vikram Narayan, MD, expanded on his data regarding nadofaragene and NMIBC published at this year’s SUO Meeting.
Declan Murphy discusses the accuracy findings from the proPSMA study presented at the 2020 SUO Meeting.
The study was designed to determine the impact of a rurally focused telemedicine program on patient outcomes.
Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.
At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.
Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.
Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.
Declan Murphy talked about the future of PSMA theranostics to target metastatic castration-resistant prostate cancer.
Narayan discusses what he thinks the future of nadofaragene firadenovec and bladder cancer are at this year’s SUO Meeting.
The study assessed the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center.
The study sought to determine the impact of a rurally focused telemedicine program on patient outcomes.
Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.
Data for a key study secondary outcome measure showed that 56.1% of patients who achieved a complete response to Jelmyto maintained that response at 12 months.
The kidney cancer expert from the National Cancer Institute spoke about what ongoing research in the field of kidney cancer is most encouraging and where research should continue to be focused.
Researchers identified the prevalence of germline mutations associated with the early-onset renal cell carcinoma, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.
A phase 2 study found that the investigational HIF-2α inhibitor MK-6482 has durable efficacy in patients with Von Hippel-Lindau associated clear cell renal cell carcinoma and non-renal lesions.
Gadzinski spoke about the most exciting aspect of the research coming out of the 21st Annual Meeting of the Society of Urologic Oncology (SUO).
A clear and reliable biomarker to select patients with prostate cancer for active surveillance or focal therapy has not yet been determined but inferring a course of action from existing biomarkers may be possible.
A study presented at the 21st Annual Meeting of the Society of Urologic Oncology found that the implementation of telemedicine was able to significantly reduce or eliminate travel and financial burdens for patients seeking quality urologic cancer care.
The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.
The procedure provided effective, long-term local control for patients with localized penile cancer, highlighting the need for a multidisciplinary approach to patient care.
Research shows that the PARP inhibitor demonstrated superior PFS and OS for patients with metastatic castration-resistant prostate cancer with BRCA1, BRCA2, or ATM alterations.
An update on the PROSPER trial analyzing enzalutamide plus androgen deprivation therapy found a lower risk of death than placebo for patients with non-metastatic CRPC.
“Providers should consider using BLC for surveillance of high-risk NMIBC patients undergoing BCG as it could change clinical management by identifying patients who are BCG unresponsive and eligible for alternative therapy and clinical trials,” said Meera Chappidi, MD.
Deep-learning algorithms could be used to alert pathologists to suspicious areas of cancer burden prior to clinical assessment, according to Nitin K. Yerram, MD.
